[pause] >> if there is a motion and a second, is there any public comment? seeing none, do a roll call vote. president clench? >> yes. >> commissioner lee? >> yes. >> commissioner mar? >> yes. >> commissioner mccarthy? >> yes. >> commissioner mccray? >> yes. >> and commissioner walker? >> yes. >> that motion carries unanimously. item f, rehearing request, case no. 6 757, 130 bueler street, [speaker not understood], san francisco, california. [speaker not understood] 67 57 previously addressed by the

abatement appeals board on june 20th, 2012. >> again, this is 130, 132 bueler street. it came up and it was already heard one time. there was a granting of the order of abatement, so forth. the property owner was given a time frame to complete the work. the property owner has now requested to rehear the abatement appeals again, but in the meantime has requested a delay due to the holidays, requested a delay for this hearing due to the holidays. it was put in writing and it was approved already. by mr. sweeney. >> commissioner mar? >> did she move? >> getting any permits or apply for any permits or anything?

>> she has not applied for any permits. >> i have a question for counsel. does the rehearing request stay our action? >> i believe it does. >> and there is a deadline for rehearing? for requesting a rehearing? >> yes, but i can't tell you what it is right off the top of my head. i think she complied -- my recollection is she complied with the time frame for requesting a rehearing. >> and now she's continuing it? >> my understanding is on september seventh, requested a continuance based on the fact that because of the high holy days. >> so, she knew when she scheduled it when it was going to be or no? my concern is that this is a delaying tactic and i wonder -- i guess we have to allow for a

continuance request. but my concern is what it does to implementing our decision. so, if it stays our decision, i guess, do we have to grant a continuance? * 7th >> no. however, given the building department has agreed to it -- >> okay. >> and given the reasons. >> okay. >> you can do what you want, but it might be problematic. i understand where you're coming from, but, yeah. >> before we even ask that, do we know, does she lift the request -- the reason for her asking for a rehearing or should that be discussed?

* list >> this is for continuance. is there a reason why she's asking for a rehearing, or do we have to discuss that when we continue the matter? >> basically in terms of her grounds for rehearing, is that what you're -- so, we have -- i think you all have in your packet, it's like third or fourth page to the back. it says to suspend -- her state the reasons why. suspend order of abatement and waive all fees if no hazard exists or at least until tenant vacates. that is the sum total of her reasons for requesting rehearing. >> i don't see any grounds for

opening the repealed item. so, i would tend to say no to a continuance as well. but i'll defer to the rest of the commissioners if you feel we should as a courtesy continue the matter for the appellant, we could. >> so, let me ask a question about it. we made a decision with the time frame. if indeed when we do hear the rehearing, do we shift back to the original time frame, or does it -- i think it was six months of the date of the hearing or something like that. >> i'm not sure. i'll have to look into that. i can't tell you that off the top of my head. but i know that what's before you right now is not the rehearing. it's a request for rehearing. so, we're kind of a couple of steps away, unfortunately, because you'd have to decide to grant rehearing and my understanding is that then wouldn't be instantaneous.

it would be set for rehearing. >> okay. why don't we do this. we'll grant one continuance. >> for 30 days. >> let's do one. >> and i would like to do it with the understanding that the clock started when we had the original hearing. if that's legal. >> i'll have to look into it. >> okay. i make a move we continue it for 30 days. >> is there a second? >> second. >> is there any public comment? seeing none, are all in favor to grant the continuance for 30 days? >> aye. >> any opposed? continuance is granted. >> thank you. >> item g, general public comment. is there any general public

comment on items that are not on the abatement appeals agenda? abatement appeals. is this for abatement appeals, though? okay, thank you. seeing none, item h, adjournment. is there a motion to adjourn? >> move to adjourn. >> second. >> second. >> i don't see any public comment. we are now adjourned at 9:50 a.m. and we'll have a brief recess to set up for the building inspection commission. [adjourned]

x it's my privilege to welcome and thank you, mayor lee, deputy director with the governor's office of economic office, lewis stewart, gale maderas, qb3's regkelly and esteemed colleagues of the city and dr. andres bush and the drug discovery leadership and our employees for joining us on this exciting occasion, the

next step of expanding the innovation in mission bay. today is notust about the launch coelaborate , but thanks to mission bay's reputation as the hub, the area has become one of the most dynamic clusters of scientific innovation as witnessed by pfizer and the continued expansion of nektar and growing start-up companies that number over 30 many mission bay alone complimented by ucsf and three new hospitals here in mission bay. we're thrilled as of today mission bay can add the colaborator to its growing in

the area and for bayer this is another step in the company's greatest history of leadership and development and our partnering of life science firms. today we'll start the clock on what we'll hope will be a longlar of collaboration between bay area and the most innovative companies in the area. before we introduce the first companies to occupy the area -- -- >> thank you, terry. i guess as everybody knows here, bayer has next year a history of 150 years' of successful r&d. i can assure everybody things have changed how we do r&d over the past 150 years, some things remain the same, which is you

need great people talking to each other, networking and when we took a little while ago the decision to move here, it was for very simple reason. we understood that director kelly was not willing to move the whole qb3 do richmond. [ laughter ] as a consequence we wanted to have our scientists in the midst of wonderful, very inspiring campus. however, we never really gave up on the idea of getting creative young people, young start-ups to us. and this is now happening today. establishing the collaborator will mean that we'll attract young companies working together with us on a great campus, getting inspired with great networks and helping us with the purpose of all of our doings, which is identifying breakthrough innovation for the patients which need it the

most. i am extremely excited and i hope that everybody understands how important this step is for us. everybody sees that my entire management team is here, everybody understands that we have the unbelievable honor of having mayor ed lee here today, who also wants to speak to us on this event. i think we should all be proud of what we have accomplished, establishing our own group here. what we want to accomplish, establishing the collaborator. i really hope that at the end, the big benefit will go to our patient. thank you very much. i'm very happy that mayor ed lee is here and speaks to us. thank you. >> thank you, andy. welcome everybody. you know, i still marvel, terry, and andy, at just less than ten years ago i was at dpw and we were signing off and getting rid of my mission bay

driving range. signing off on getting rid of the railroads and turning this over to what was visualized by mayor brown and then gavin newsom later as the place that we're going to really create life sciences and now today, just seeing what with bay area is doing and the innovations that they have at really putting in the meat of why we all our city the innovation capital of the world. it's not your bay area and pfizer working alone, but they are literally using their drugs and their development of drugs to really incentivize the therapeutic uses and just like with the other tech companies, this is a very successful model that is happening between big and small, established and new.

the collaboration that is going to go on here, i'm excited about this. it will especially with the two companies that you are naming today and i have to admit, terry, that when i heard prolynx was here, i thought you have finally gotten a replacement for the driving range -- you have to be a golfer to understand that. [ laughter ]. and aronora, these are very important discoveries and therapeutic uses of medin that medicine that will advance our world and 38 of them here in mission bay on a vision that i inherited, but so glad to come to fruition.

these great incubators will provide information for future generations. i know. it it's right here happening in san francisco and at the same time, while we visualize the kind of push-button to some of these solutions, you have got to see how the laboratory discoveries and the very high-levels of disciplines that are happening in these laboratories. and in the constant conversation between these different disciplines that are going on. ends up to be these great discoveries of it's exciting. it's our future. it's what we had envisioned when gavin said regenerative medicine right here in our bay, the stem-cell research going on and the association with uc san francisco that is part of your work that is happening right here. so i don't mind if i come down here every week to find out what the newest

discovery is. it's amazing for the city and always places us on the map. i get to talk about this whether i'm at the u.s. conference of mayors or the democratic national convention, everybody is interested in what san francisco is doing from music to art to life sciences and clearly showing the way for our new ventures that offer even the best jobs to be created right here in san francisco. so thank you, bayer. thank you for being part of this wonderful, wonderful mix. it's my appreciate ion for you to be here and continue to support you here and how much this has become very much a part of our city. thank you very much. [ applause ] >> mayor lee, friends and colleagues and neighbors, and

partners and people who are interested in partnering with us with bayer, today is a great day. today is a day that when an idea comes relative and concrete. you can feel it and touch it and the idea goes back to terry and chris. and i'm very happy to be a part of it today. as you know, bayer is really committed to innovation and knowing the intricacies of science ever growing and becoming more complicated. it's pretty clear that we must reach out and compliment our internal research strengths with partners, partners from academia and tech and collaborations with academia part of our research. it's not just an incubator model, but collaboration with mutual fit of interests. we help each other really for the benefit of the patients,

which is really our ultimate goal to bring treatment to the impairments. the collaborator is one of the newest models that we pursue. it's an addition to our partnering models which cover actually pretty wide spans. another example i want to give you is our grants for targets initiative, where we use the internet, really to reach out into the whole crowd of scientists, worldwide, and the collaborator is our newest addition. we do have other forms of collaboration beyond of course the collaborator and the grants for targets initiative. for example, the imi initiative in europe actually goes beyond the collaboration of individual companies forming consortia of academia and large companies where the individual partner is just too small. but focusing on this area of course, the san francisco area

and mayor lee already alluded to that is a hotspot and it's extremely important. we have been here for a long time and our activities here with just four projects with ucsf last year with our partnerships are testament to that commitment to this area. and again, the collaborator is just testament to our commitment to bring treatments to the patients and we use any kind of model that fits that purpose and makes us more productive in that endeavor. thank you. chris, please. [ applause ] >> thank you. so we have heard from my colleagues that collaboration and innovation are real priorities for bayer's research and development and

using these values that are important for us. the collaborator is just an incubator, but we're trying to put a new twist on this with the landlord-tenant relationship and there really no better place to do this and to be part of the growing bioecosystem it than here in mission bay of the whole point of this is to have tenant companies, start-up companies that want to partner with bayer with proximity to our research groups in this building and in addition, can access the global expertise of bayer scientist, as well as the infrastructure that bayer brings and dr. bush mentioned that we have had for 150 years. we are also looking to put companis in the collaborator that are not necessarily partners yet, but again, what better way to find proper probings to work on than having scientists in the same building interacting with each other? as we'll open up the space for tours the collaborator is an

open-floor space that encourages interact between the start-up companies in the space. but more importantly what it brings to mission bay is the ability to interact with the 30 other start-ups here, with ucsf, and their core facilities and with incredible organizations like gladstone and qb3. really if you think about it, there probably isn't a better place in the world for a start-up company to become successful than here in mission bay. what you see here in front of me is the collaborator roster. and this will house the logos of the start-up companies that will be the first to utilize the space. i will invite them up in a minute. aronora is developing drugs that hold the promise to prevent the growth of blood clots without some of the thrombotic side effects of

bleeding. prolynx is manufacturing custom drivers - no, they are not. [ laughter ] >> exactly. statement sorry, i'm putting you in a hole now. you have to develop that as a side project. prolynx is developing technology that get as round many of the problems with conjugated drugs and develop technology for the sustained release of drugs that you can control circulating levels and it's tuneable. so can you optimize it for each project. so with that, i would actually like to invite up aronora and prolynx. [ applause ]

>> you have heard mention from some of my colleagues -- one second -- that time is of the essence and that we are in a race to deliver the therapies

to the patients and we have a clock that reminds us that we're us on the clock and time is of the essence. i would like to invite the other four speakers up to help me start the clock, that will be a reminder of what i mentioned. 3, 2, 1 ! >> is it working? >> yes, it is. [ laughter ] >> it is working. trust me, it's working. trust me, it's working. [ laughter ] so in a few minutes we'll be opening up the doors to the building over there behind the registration desk. and i welcome you to come in

and take a look at the space. and ask any questions of colleagues that are in there. thank you very much for coming.

([inaudible]. >> instructor: the staff is asking for a one week continuance, the 27th of september, also further on your

calendar, commissioner, item 18 on the corrected calendar, case number 2011 [inaudible] clay street, it's my understanding that the project sponsor has requested a one week continuance because they're trying to work out an agreement and staff is requesting a further continuance to the 27th of september, with that, commissioners, i'm not aware of any other matter on the calendar for continuance. >> are any other items on the calendar that are proposed for continuance. seeing none, commissioner borden. >> i have a question before i make a motion, why is the last item, the one item being proposed to may, that's far off.

>> i'm david lindsay from the department staff, the property owners currently live in london and they're working from there trying to resolve this with the dr requester, it was the project sponsor that is requested this date out in may. they are looking at an option that would require a variance so i think the plan is for the project sponsor to file a variance application, go through that process and see where they are. >> okay. with that, i will move to continue items 1 to the date on the calendar, item 2 to october 18th, item 3 to october 4 and item 4 to the date on the calendar, and then continue item 12 to september 27th and item 18th also to october 27.